Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

The market for obesity drugs may soon reach almost $100 billion.

Eli Lilly execs believe the first oral version of their blockbuster GLP-1 drugs won't cannibalize sales of the injectables ...

Eli Lilly (NYSE:LLY) is committing over $3.5b to a new manufacturing facility in Pennsylvania’s Lehigh Valley focused on next generation injectable medicines. The company has entered collaborations ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has ...

Indiana Attorney General Todd Rokita appeared on Hammer and Nigel to discuss his recent lawsuit against Eli Lilly, centering ...

The Indianapolis-based drugmaker reported revenue of $19.3 billion — up 43% from the same period a year ago, driven by growth ...

The stock price has climbed in the triple digits over three years.

Attorney General Todd Rokita is suing one of Indiana's largest companies, Eli Lilly and Co., alleging the company conspired with other drug manufacturers to artificially inflate the price of insulin ...

Drugmaker Eli Lilly and Co. says the $3.5 billion manufacturing facility in Fogelsville, just outside Allentown, will make injectable drugs and devices.